GO
Loading...

Gilead Sciences Inc

More

  • Final Glance: Biotechnology companies Tuesday, 31 Mar 2015 | 5:58 PM ET

    Amgen Inc. fell $4.46 or 2.7 percent, to $159.85. Biogen Idec fell $9.38 or 2.2 percent, to $422.24. Celgene Corp. fell $4.74 or 3.9 percent, to $115.28.

  • Midday Glance: Biotechnology companies Tuesday, 31 Mar 2015 | 2:47 PM ET

    Amgen Inc. fell $3.17 or 1.9 percent, to $161.14. Biogen Idec fell $1.75 or. 4 percent, to $429.87. Celgene Corp. fell $3.90 or 3.2 percent, to $116.12.

  • Early Glance: Biotechnology companies Tuesday, 31 Mar 2015 | 10:29 AM ET

    Amgen Inc. fell $2.29 or 1.4 percent, to $162.02. Biogen Idec fell $2.62 or. 6 percent, to $429.00. Celgene Corp. fell $2.41 or 2.0 percent, to $117.61.

  • Final Glance: Biotechnology companies Monday, 30 Mar 2015 | 5:56 PM ET

    Amgen Inc. rose $1.72 or 1.1 percent, to $164.31. Biogen Idec rose $1.75 or. 4 percent, to $431.62. Celgene Corp. rose $1.34 or 1.1 percent, to $120.02.

  • Midday Glance: Biotechnology companies Monday, 30 Mar 2015 | 1:16 PM ET

    Amgen Inc. rose$. 93 or. 6 percent, to $163.52. Biogen Idec rose $2.22 or. 5 percent, to $432.09. Celgene Corp. rose$. 83 or. 7 percent, to $119.51.

  • Early Glance: Biotechnology companies Monday, 30 Mar 2015 | 10:56 AM ET

    Amgen Inc. rose $2.54 or 1.6 percent, to $165.13. Biogen Idec rose $4.55 or 1.1 percent, to $434.42. Celgene Corp. rose $1.49 or 1.3 percent, to $120.17.

  • The nation's largest health insurer, UnitedHealth, will muscle up for its fight against rising prescription drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp.. UnitedHealth and Catamaran said Monday that their deal will combine businesses that have "distinctive, rapidly growing specialty pharmacy services" for a...

  • Final Glance: Biotechnology companies Friday, 27 Mar 2015 | 6:10 PM ET

    Amgen Inc. rose $2.04 or 1.3 percent, to $162.59. Biogen Idec rose$. 94 or. 2 percent, to $429.87. Celgene Corp. rose $1.02 or. 9 percent, to $118.68.

  • Midday Glance: Biotechnology companies Friday, 27 Mar 2015 | 1:16 PM ET

    Amgen Inc. rose $2.20 or 1.4 percent, to $162.75. Biogen Idec rose $6.16 or 1.4 percent, to $435.09. Celgene Corp. rose $1.66 or 1.4 percent, to $119.32.

  • Final Glance: Biotechnology companies Thursday, 26 Mar 2015 | 6:07 PM ET

    Amgen Inc. fell$. 07 or percent, to $160.55. Biogen Idec fell $2.70 or. 6 percent, to $428.93. Celgene Corp. rose$. 67 or. 6 percent, to $117.66.

  • Midday Glance: Biotechnology companies Thursday, 26 Mar 2015 | 2:20 PM ET

    Amgen Inc. rose$. 17 or. 1 percent, to $160.79. Biogen Idec fell $3.13 or. 7 percent, to $428.51. Celgene Corp. rose$. 85 or. 7 percent, to $117.84.

  • March 26- French drugmaker Genfit SA said on Thursday it will begin a late stage trial later this year of its lead treatment for a liver-destroying condition, saying it failed a midstage trial in part due to its inclusion of many patients with a mild form of the disease. When adjusting for those factors, the results were "quite robust for NASH," Dean Hum, the company's...

  • Early Glance: Biotechnology companies Thursday, 26 Mar 2015 | 10:34 AM ET

    Amgen Inc. rose$. 38 or. 2 percent, to $161.00. Biogen Idec fell $6.27 or 1.5 percent, to $425.36. Celgene Corp. rose $1.13 or 1.0 percent, to $118.12.

  • March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...

  • Conatus Pharma's liver drug succeeds in mid-stage study Thursday, 26 Mar 2015 | 7:02 AM ET

    March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...

  • Final Glance: Biotechnology companies Wednesday, 25 Mar 2015 | 6:03 PM ET

    Amgen Inc. fell $5.39 or 3.2 percent, to $160.62. Biogen Idec fell $21.08 or 4.7 percent, to $431.63. Celgene Corp. fell $5.16 or 4.2 percent, to $116.99.

  • Midday Glance: Biotechnology companies Wednesday, 25 Mar 2015 | 1:43 PM ET

    Amgen Inc. fell $3.89 or 2.3 percent, to $162.13. Biogen Idec fell $19.26 or 4.3 percent, to $433.45. Celgene Corp. fell $3.99 or 3.3 percent, to $118.16.

  • Early Glance: Biotechnology companies Wednesday, 25 Mar 2015 | 11:55 AM ET

    Amgen Inc. fell $2.19 or 1.3 percent, to $163.83. Biogen Idec fell $11.90 or 2.6 percent, to $440.81. Celgene Corp. fell $1.58 or 1.3 percent, to $120.57.

  • BOSTON, March 25- CEOs at large U.S. companies collectively realized at least $6 billion more in compensation than initially estimated in annual disclosures in the five years after the financial crisis first hit, according to a Reuters analysis. About 300 CEOs who served throughout the 2009-2013 period at S&P 500 companies together realized about $22 billion...

  • Final Glance: Biotechnology companies Tuesday, 24 Mar 2015 | 8:17 PM ET

    Amgen Inc. fell$. 53 or. 3 percent, to $166.01. Biogen Idec fell $11.02 or 2.4 percent, to $452.71. Celgene Corp. fell$. 79 or. 6 percent, to $122.15.